UnitedHealth Group has implemented a more restrictive first-line coverage policy for AMVUTTRA in its Medicare Advantage plans, effective October 1, 2026. This move could delay access for new patients, reflecting the company's efforts to manage pharmacy benefits and medical costs, potentially impacting the drug's manufacturer.
UnitedHealth Group has announced a more restrictive first-line coverage policy for AMVUTTRA within its Medicare Advantage business, effective October 1, 2026. This policy change, while not affecting existing patients and including an exception process, is noted as a potential source of delay for new patients seeking the treatment. This move is significant as it reflects UNH's ongoing efforts to manage pharmacy benefits and medical costs, which could positively impact its profitability by controlling drug expenditures. For Alnylam Pharmaceuticals (ALNY), the manufacturer of AMVUTTRA, this policy could lead to slower adoption rates and reduced sales growth in the Medicare Advantage segment, posing a short-term headwind for the drug's market penetration. Traders should consider the potential for increased cost savings for UNH versus the revenue impact for ALNY, especially given the long lead time before the policy takes effect.